Canada-based Patheon has completed its agreement with AventisPharmaceuticals to provide long-term manufacturing and supply services to the latter and to purchase Aventis' pharmaceutical manufacturing and development site located in Cincinnati, Ohio, USA.
The purchase price for the facility was $16 million, subject to normal closing adjustments and the assumption of certain liabilities. The deal was financed through Patheon's existing credit facilities with its bankers and the firm has also acquired inventories of approximately $14 million, consisting of raw materials, packaging components and work in process, to be paid over the next four months and financed through working capital.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze